Brand guide
Zepbound: Complete Guide
Zepbound is the FDA-approved tirzepatide product indicated for chronic weight management in adults meeting labelled criteria, and for obstructive sleep apnoea with obesity. It is supplied as a pre-filled single-dose device for once-weekly subcutaneous injection. Its evidence base is the SURMOUNT programme, including SURMOUNT-1 and SURMOUNT-OSA.
Key takeaways
- Zepbound is FDA approved for chronic weight management and, following SURMOUNT-OSA, obstructive sleep apnoea.
- It is the same molecule as Mounjaro, approved under a different indication and brand.
- Supplied as a pre-filled device, which controls dose delivery unlike compounded vials.
- Evidence base is the SURMOUNT programme, including about 20.9% mean reduction at 15 mg in SURMOUNT-1.
- Cash price without coverage is substantially higher than compounded alternatives.
| Brand | Zepbound |
|---|---|
| Active ingredient | Tirzepatide |
| Indications | Chronic weight management; obstructive sleep apnoea with obesity |
| Presentation | Pre-filled single-dose device |
| Key trials | SURMOUNT-1, SURMOUNT-OSA |
| Manufacturer | Eli Lilly and Company |
How does Zepbound differ from Mounjaro?
They contain the same active ingredient. The difference is the approved indication: Zepbound for chronic weight management and obstructive sleep apnoea with obesity, Mounjaro for type 2 diabetes. Brand, packaging, and pricing differ accordingly, as does insurance coverage — weight-management indications have historically faced more coverage resistance than diabetes indications.
What does the device presentation actually buy you?
Dose control. A pre-filled single-dose device delivers a defined amount without the patient measuring anything. That removes the dose-measurement error pathway that exists when drawing from a compounded vial, where concentration variation and unit confusion have produced reported errors.
It is one of the concrete differences between an approved product and a compounded preparation, alongside verified manufacturing and systematic adverse-event reporting.
What does Zepbound cost?
Cash prices without coverage are substantially higher than compounded alternatives, and manufacturer savings programmes and direct cash-pay channels change the figure considerably for eligible people. Coverage is the largest variable — see insurance coverage and savings programmes.
What the evidence shows
- FDA approval for defined indications with a supporting trial programme.
- Device-controlled dose delivery.
What the evidence does not show
- That compounded tirzepatide is equivalent to Zepbound.
- A current price — pricing and coverage vary and change.
Related: Mounjaro · Versus compounded
What does the market actually charge?
| Group | $/month |
|---|---|
| TRYM Health | 125 |
| NexLife | 186 |
| Fridays | 240 |
| Mochi Health | 278 |
| Eden | 298 |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Monthly membership fee | $79 | $178 |
| Consultation fee | $0 | $178 |
| Shipping | $0 | $178 |
| Series | Start | 6 mo | 12 mo | 18 mo | 24 mo |
|---|---|---|---|---|---|
| TRYM Health | 0$ | 750.0$ | 1500.0$ | 2250.0$ | 3000.0$ |
| NexLife | 0$ | 1116.0$ | 2232.0$ | 3348.0$ | 4464.0$ |
| Fridays | 0$ | 1440.0$ | 2880.0$ | 4320.0$ | 5760.0$ |
| Product | Regulatory status | What that means for availability |
|---|---|---|
| Zepbound (tirzepatide) | FDA approved for chronic weight management | Available by prescription through normal pharmacy channels |
| Mounjaro (tirzepatide) | FDA approved for type 2 diabetes | Available by prescription through normal pharmacy channels |
| Compounded tirzepatide injection | Not FDA approved; shortage resolved, enforcement discretion ended | Routine compounding no longer permitted as an essentially-a-copy product |
| Compounded oral, sublingual, ODT or troche tirzepatide | Not FDA approved in any form | Never covered by shortage-era compounding; no approved oral tirzepatide product exists |
| Research-grade or grey-market tirzepatide | Not a medicine; outside the regulated supply chain | No pharmacy accountability, no verified identity, purity, or sterility |
Why is tirzepatide pricing so hard to compare?
Four structural features of this market make direct comparison difficult, and none of them is accidental. Prices are frequently advertised as a starting figure that applies to a subset of doses or commitment lengths. Medication and service are often billed separately, so the headline covers part of the cost. Introductory rates differ from recurring rates, and the introductory figure is the one displayed. And commitment tiers convert a monthly price into a prepayment, which changes what the number means.
The combined effect is that two advertised figures can differ by a factor of two while the actual recurring costs are nearly identical, or appear nearly identical while the actual costs differ substantially. This is why every figure on this site is normalised before it is compared, and why providers whose figures cannot be normalised are excluded rather than estimated.
| Cost component | Typically advertised? | Typically included in the headline? | Effect on real cost |
|---|---|---|---|
| Medication | Yes | Sometimes | The base figure |
| Membership or programme fee | Sometimes | Rarely | Commonly $40-$80 per month |
| Initial consultation | Sometimes | Rarely | One-off, but can be substantial |
| Shipping | Sometimes | Varies | Small but recurring |
| Dose surcharge above a threshold | Rarely | Almost never | Can change which provider is cheapest |
| Laboratory work | Rarely | No | Variable, sometimes billed to insurance |
| Renewal after introductory period | Rarely displayed | No | Frequently the largest single jump |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Recurring membership fee | $79 | $178 |
| Shipping, billed monthly | $10 | $188 |
What does treatment cost over a realistic horizon?
Because SURMOUNT-4 established that stopping produces substantial regain, the planning horizon for tirzepatide is years rather than months. A monthly difference that looks trivial compounds into a material sum across that period, and an introductory discount that looks generous becomes close to irrelevant.
| Provider | Monthly | One year | Two years | Three years |
|---|---|---|---|---|
| TRYM Health | $125 | $1,500 | $3,000 | $4,500 |
| NexLife | $186 | $2,232 | $4,464 | $6,696 |
| Fridays | $240 | $2,880 | $5,760 | $8,640 |
| Mochi Health | $278 | $3,336 | $6,672 | $10,008 |
| Eden | $298 | $3,576 | $7,152 | $10,728 |
These projections assume the price and the dose are unchanged, and neither is guaranteed. Dose coverage is unverified for most providers in this dataset, and a surcharge that applies above a dose threshold would raise the later years of every column. The projection is therefore a floor rather than a forecast.
What does this page cover, and what does it deliberately leave out?
This page addresses Indications, dosing, evidence, safety, cost and coverage and device, organised around the primary question of Zepbound. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Indications | Covered on this page | Captured record |
| Dosing | Covered on this page | Captured record |
| Evidence | Covered on this page | Captured record |
| Safety | Covered on this page | Captured record |
| Cost | Covered on this page | Captured record |
| Coverage and device | Covered on this page | Captured record |
| Individualized clinical instruction | Deliberately not covered | Belongs with your insurer and the provider |
What are the limits of what this page can tell you?
Every page on this site rests on a specific captured pricing and coverage rules, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for your insurer and the provider.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on Zepbound.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 6 technical terms this page uses, including 503A, 503B, compounded, effective monthly cost — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
| subcutaneous | Beneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. |
Frequently asked questions
What is Zepbound approved for?
Chronic weight management in adults meeting labelled criteria, and obstructive sleep apnoea with obesity.
Is Zepbound the same as Mounjaro?
Same active ingredient, different approved indication and brand.
Why is Zepbound more expensive than compounded tirzepatide?
Approved-drug pricing reflects development, approval, and manufacturing cost structures and is set against insurance reimbursement.
Does the pen make a difference?
It controls dose delivery, removing the measurement-error pathway present with compounded vials.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.